Posted On: July 2, 2009
Push for Singulair to receive black box warning
The FDA recently warned the makers of Singulair and three other asthma drugs that the labels must include a dozen mood and behavior changes as possible product side effects. Users of the drugs have experienced severe behavioral product side effects and now there is a push for the drugs to contain a more severe warning.
To read more about the black box warning push.
